Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been given a consensus rating of “Moderate Buy” by the five ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $5.67.

Separately, HC Wainwright decreased their target price on shares of Karyopharm Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, March 1st.

Insider Activity at Karyopharm Therapeutics

In related news, CEO Richard A. Paulson sold 80,470 shares of Karyopharm Therapeutics stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $1.17, for a total value of $94,149.90. Following the completion of the sale, the chief executive officer now owns 1,183,783 shares of the company’s stock, valued at approximately $1,385,026.11. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CFO Michael Mason sold 27,687 shares of Karyopharm Therapeutics stock in a transaction on Thursday, February 29th. The shares were sold at an average price of $1.17, for a total value of $32,393.79. Following the transaction, the chief financial officer now owns 404,918 shares in the company, valued at approximately $473,754.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Richard A. Paulson sold 80,470 shares of Karyopharm Therapeutics stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $1.17, for a total transaction of $94,149.90. Following the completion of the transaction, the chief executive officer now owns 1,183,783 shares in the company, valued at approximately $1,385,026.11. The disclosure for this sale can be found here. In the last 90 days, insiders sold 164,542 shares of company stock valued at $198,175. Insiders own 3.32% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. GSA Capital Partners LLP raised its holdings in Karyopharm Therapeutics by 311.4% in the 4th quarter. GSA Capital Partners LLP now owns 2,337,985 shares of the company’s stock worth $2,022,000 after acquiring an additional 1,769,687 shares during the period. Northern Trust Corp raised its holdings in Karyopharm Therapeutics by 1.1% in the 4th quarter. Northern Trust Corp now owns 996,147 shares of the company’s stock worth $862,000 after acquiring an additional 10,415 shares during the period. Monashee Investment Management LLC bought a new position in Karyopharm Therapeutics in the 4th quarter worth $115,000. Panagora Asset Management Inc. bought a new position in Karyopharm Therapeutics in the 4th quarter worth $197,000. Finally, BNP Paribas Financial Markets raised its holdings in Karyopharm Therapeutics by 6.5% in the 4th quarter. BNP Paribas Financial Markets now owns 1,769,184 shares of the company’s stock worth $1,530,000 after acquiring an additional 108,286 shares during the period. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Stock Performance

Karyopharm Therapeutics stock opened at $1.17 on Friday. The company has a 50 day moving average price of $1.34 and a 200 day moving average price of $1.06. The firm has a market capitalization of $134.63 million, a price-to-earnings ratio of -0.94 and a beta of 0.03. Karyopharm Therapeutics has a 52 week low of $0.62 and a 52 week high of $4.11.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its earnings results on Thursday, February 29th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). The business had revenue of $33.75 million for the quarter, compared to the consensus estimate of $33.50 million. During the same period in the prior year, the business earned ($0.43) earnings per share. Equities analysts forecast that Karyopharm Therapeutics will post -1.19 earnings per share for the current fiscal year.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).